WallStreetZenWallStreetZen

NASDAQ: BIIB
Biogen Inc Stock

$270.03+4.86 (+1.83%)
Updated Mar 24, 2023
BIIB Price
$270.03
Fair Value Price
$293.64
Market Cap
$39.02B
52 Week Low
$187.16
52 Week High
$311.88
P/E
12.88x
P/B
2.91x
P/S
3.96x
PEG
1.48x
Dividend Yield
N/A
Revenue
$10.17B
Earnings
$3.05B
Gross Margin
77.6%
Operating Margin
36.17%
Profit Margin
29.9%
Debt to Equity
0.83
Operating Cash Flow
$1B
Beta
0.85
Next Earnings
May 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A

BIIB Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (37)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIIB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BIIB ($270.03) is undervalued by 8.04% relative to our estimate of its Fair Value price of $293.64 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BIIB ($270.03) is not significantly undervalued (8.04%) relative to our estimate of its Fair Value price of $293.64 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BIIB ($270.03) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIIB due diligence checks available for Premium users.

Be the first to know about important BIIB news, forecast changes, insider trades & much more!

BIIB News

Valuation

BIIB fair value

Fair Value of BIIB stock based on Discounted Cash Flow (DCF)
Price
$270.03
Fair Value
$293.64
Undervalued by
8.04%
BIIB ($270.03) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIIB ($270.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIIB ($270.03) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BIIB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
12.88x
Industry
26.79x
Market
21.37x
BIIB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BIIB is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

BIIB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.91x
Industry
4.89x
BIIB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BIIB price to earnings growth (PEG)

For valuing profitable companies with growth potential
BIIB is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

BIIB's financial health

Profit margin

Revenue
$2.5B
Net Income
$550.4M
Profit Margin
21.6%
BIIB's Earnings (EBIT) of $3.68B... subscribe to Premium to read more.
Interest Coverage Financials
BIIB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$24.6B
Liabilities
$11.2B
Debt to equity
0.83
BIIB's short-term assets ($9.79B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIIB's short-term assets ($9.79B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIIB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BIIB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$175.0M
Investing
-$141.1M
Financing
-$7.4M
BIIB's operating cash flow ($1.38B)... subscribe to Premium to read more.
Debt Coverage Financials

BIIB vs General Drug Manufacturer Stocks

TickerMarket Cap1d %P/EP/B
BIIB$39.02B+1.83%12.88x2.91x
HZNP$24.79B+0.67%47.60x4.89x
GSK$69.21B-2.39%3.84x5.42x
OGN$5.56B+2.05%6.06x-6.23x
GRFS$4.71B-1.15%22.53x0.78x

Biogen Stock FAQ

What is Biogen's quote symbol?

NASDAQ: BIIB) Biogen trades on the NASDAQ under the ticker symbol BIIB. Biogen stock quotes can also be displayed as NASDAQ: BIIB.

If you're new to stock investing, here's how to buy Biogen stock.

What is the 52 week high and low for Biogen (NASDAQ: BIIB)?

(NASDAQ: BIIB) Biogen's 52-week high was $311.88, and its 52-week low was $187.16. It is currently -13.42% from its 52-week high and 44.28% from its 52-week low.

How much is Biogen stock worth today?

(NASDAQ: BIIB) Biogen currently has 144,485,646 outstanding shares. With Biogen stock trading at $270.03 per share, the total value of Biogen stock (market capitalization) is $39.02B.

Biogen stock was originally listed at a price of $5.73 in Dec 31, 1997. If you had invested in Biogen stock at $5.73, your return over the last 25 years would have been 4,612.57%, for an annualized return of 16.66% (not including any dividends or dividend reinvestments).

How much is Biogen's stock price per share?

(NASDAQ: BIIB) Biogen stock price per share is $270.03 today (as of Mar 24, 2023).

What is Biogen's Market Cap?

(NASDAQ: BIIB) Biogen's market cap is $39.02B, as of Mar 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biogen's market cap is calculated by multiplying BIIB's current stock price of $270.03 by BIIB's total outstanding shares of 144,485,646.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.